Beta
Tuberculosis medications
medication Under reviewTuberculosis medications are pharmaceutical drugs used to treat and prevent tuberculosis, a bacterial infection caused by Mycobacterium tuberculosis primarily affecting the lungs. These include first-line agents like isoniazid, rifampin, ethambutol, and pyrazinamide for drug-susceptible TB, as well as newer agents such as bedaquiline and delamanid for multidrug-resistant TB. They work by targeting essential bacterial processes, including cell wall synthesis, DNA transcription, and energy metabolism, to eradicate the pathogen and prevent resistance development. General health applications focus on shortening treatment durations from the traditional 6-9 months to 4-9 months with all-oral regimens, improving patient adherence, reducing toxicity, and minimizing drug interactions. Shorter regimens incorporating bedaquiline, moxifloxacin, linezolid, and pretomanid have shown promise in treating drug-susceptible and resistant forms, particularly in high-burden regions, while preventive uses target exposed household contacts and high-risk groups like those with HIV.
Research summary
Scientific evidence from large-scale phase 3 trials demonstrates that novel shorter regimens with bedaquiline, delamanid, pretomanid, linezolid, moxifloxacin, and rifapentine are as effective as standard longer treatments for drug-susceptible and rifampin-resistant TB, with improved safety profiles. Consensus supports their use in guidelines, though most data come from TB patients rather than healthy subjects; phase 1 safety studies in healthy volunteers confirm tolerability of individual agents like TBA-7371 and telacebec.
No side effects tracked yet
No side effects have been reported by studies or users for this habit yet.
Research
No studies found yet. Request research to discover relevant studies.
Community updates
No updates yet for this supplement.
Be the first to share your experience!